Pfizer's Earnings Beat Dampened by Prevnar Shortfall

Pfizer topped second-quarter earnings estimates thanks to strong sales of for two of the company's newer drugs, but got bad news on sales of its Prevnar vaccine. Bloomberg's Drew Armstrong examines the results on "Bloomberg ‹GO›." (Source: Bloomberg)

How to Trade Microsoft Ahead of Earnings
57:10 - Kelly & Co. Managing Partner Kevin Kelly discusses a potential deal between Sprint and T-Mobile and his options trade for Microsoft. He speaks with Bloomberg's Julie Hyman on "Bloomberg Markets." (Source: Bloomberg)
  • Full Show: Surveillance (09/18)
  • Full Show: What'd You Miss? (09/15)
  • Full Show: Bloomberg Daybreak: Americas (09/15)